An 82-year-old woman with pulmonary aspergillosis developed rhabdomyolysis, manifested by dark urine and markedly elevated creatine kinase (3,125 U/l) and myoglobin (3,884.4 ng/ml) levels, after administration of micafungin. At the same time, delayed myocardial damage appeared, confirmed by a high level of high-sensitivity troponin I (26,301.6 pg/ml). After discontinuation of micafungin, symptoms subsided and biomarkers normalized. This case is the first reported case of micafungin-induced rhabdomyolysis and myocardial injury. The authors emphasize the need for increased vigilance when administering micafungin to elderly patients with multiple diseases and polypharmacy. This case adds to the knowledge of the safety profile of micafungin.